Answers are grounded in this paper and cite their sources.
Immune-checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) have substantially improved outcomes for patients with multiple cancer types; however, primary (intrinsic) resistance remains common and limits durable responses. Mechanistically, such resistance can arise from impaired interferon-γ signaling (including Janus kinases-signal transducer and activator of transcription dysfunction), tumor-intrinsic oncogenic pathway alterations [e.g., phosphatase and tensin homolog (PTEN) loss with downstream phosphoinositide 3-kinase/protein kinase B hyperactivation and Wnt/β-catenin-associated immune escape], and tumor-extrinsic immunosuppression mediated by PD-L1-upregulated suppressive myeloid populations such as myeloid-derived suppressor cells. These pathways converge on reduced T-cell effector function, compromised immune recognition, and reinforcement of an immunosuppressive tumor microenvironment (TME), collectively diminishing the clinical benefit of PD-1/PD-L1 blockade. In this review, we synthesize current evidence on primary (intrinsic) resistance to PD-1/PD-L1 blockade and discuss how nanomaterial-enabled interventions can be mechanistically matched to these resistance determinants. The nanotechnology-based therapeutic strategies were classified as four categories: (i) modulation of resistance-associated signaling pathways; (ii) direct blockade/interception of the PD-1/PD-L1 axis; (iii) immune-checkpoint gene silencing; and (iv) TME reprogramming.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: